CARDIAC BIOMARKERS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Global Cardiac Biomarkers Market Size and Forecast 2026-2033

The global cardiac biomarkers market is estimated to be valued at USD 19.49 Bn in 2026 and is expected to reach USD 47.87 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 13.7% from 2026 to 2033.

Key Takeaways of the Global Cardiac Biomarkers Market

• In terms of application, myocardial infarction is expected to contribute the highest share of the market, accounting for 37% in 2026.
• In terms of location of testing, laboratory testing is expected to contribute the highest share of the market, accounting for 71.6% of the market share in 2026.
• North America is projected to be the leading region in the global cardiac biomarkers market with an expected share of 40.7% in 2026.

Market Overview

The increasing prevalence of cardiovascular diseases and the growing demand for point-of-care testing are the major factors contributing to the market growth. The market is witnessing various trends such as increased adoption of high sensitivity troponin tests and launch of novel cardiac biomarkers by key players.

Moreover, rising investments by public and private players to develop innovative biomarkers with high sensitivity and specificity for accurate detection of acute myocardial infarction and other heart conditions are expected to offer lucrative opportunities for the market players over the forecast period.

Market Concentration and Competitive Landscape

Impact of AI on the Global Cardiac Biomarkers Market

AI is revolutionizing cardiac diagnostics, especially in biomarkers, enhancing accuracy, efficiency, and predictive capabilities

• Siemens Healthineers uses AI in point-of-care cardiac biomarker testing, enabling faster on-site analysis of markers like Troponin I to quickly identify acute cardiac conditions and support timely interventions.
• Abbott’s AI-enhanced Troponin-I assay helps clinicians assess patient risk levels in real time, leading to faster diagnosis, fewer unnecessary admissions, and smoother emergency department workflows.
• Companies like Roche, Siemens, and Abbott are leveraging AI to improve accuracy, speed, and predictive power in cardiac diagnostics, driving earlier interventions and better patient outcomes.

Comparative Analysis of FDA, EMA, and Emerging Market Approval Pathways for Cardiac Biomarker Diagnostics

Current Events and Their Impact on the Global Cardiac Biomarkers Market

Emerging Applications of the Global Cardiac Biomarkers Market

The cardiac biomarkers market is moving towards specialized, high-potential applications that are currently underutilized.

• Emerging applications include using biomarkers to monitor the effectiveness of anti-obesity drugs (like GLP-1 receptor agonists), supporting CRISPR gene therapy by tracking cardiac strain, and employing AI with high-sensitivity troponin for asymptomatic risk stratification.
• Future applications are expected to involve multi-analyte panels for more precise diagnostics, wearable devices for continuous non-invasive biomarker tracking, and point-of-care testing.

Pipeline Analysis

Key Pricing Determinants

Market Trends 

Increasing Burden of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases is one of the major drivers of growth in the cardiac biomarkers market. According to the World Health Organization, cardiovascular diseases account for over 17 million deaths each year, which is estimated to grow to over 23.6 million by 2030.

The key factors responsible for the rising cardiovascular disease burden include rapidly aging populations, increasing adoption of sedentary lifestyles and unhealthy diets, rising stress levels, smoking, and a growing prevalence of conditions like obesity and diabetes.

Rising Focus on Innovation and Development of Novel Biomarkers

The growing focus of leading industry players and research institutions on innovation and development of novel cardiac biomarkers is another major factor fueling the growth of this market. Currently available biomarker tests only facilitate the detection of myocardial necrosis and injury.

However, clinicians also require biomarkers that can provide accurate information on other aspects such as myocardial stress, ischemia, remodeling, and other pre-damage states. The development of panels of multiple biomarkers is also gaining attention for facilitating comprehensive cardiac risk assessment.

Market Opportunity: Development of novel cardiac biomarkers

The novel cardiac biomarkers are poised to revolutionize the global market by enabling early prediction of cardiac events, unlike current biomarkers such as Troponin and CK-MB, which only indicate injury after symptoms appear.

For instance, ST2 and Galectin-3 show promise in predicting heart failure exacerbations days in advance, offering a critical window for intervention. This shift towards predictive biomarkers is vital, considering cardiovascular diseases cause 17.9 million deaths annually worldwide, with nearly half occurring prematurely.

Segment Analysis

Global Cardiac Biomarkers Market Insights, by Product Type

In terms of product type, Myocardial Muscle Creatine Kinase segment is expected to contribute the highest share of the market, accounting for 37% in 2026. This is owing to their higher sensitivity and specificity compared to other cardiac biomarkers.

Troponins, including Troponin T and Troponin I, are regulatory proteins that control the contractions of cardiac muscle. Even small amounts of Troponin released into the bloodstream can accurately indicate damage to the heart muscle. This makes Troponins the gold standard for the diagnosis of myocardial infarction as they can detect any heart muscle damage within 4-6 hours of the onset of chest pain. This increased diagnostic resolution provided by Troponins tests further expands their role in diagnosing conditions like unstable angina or detecting re-infarctions.

Global Cardiac Biomarkers Market Insights, by Application

In terms of application, myocardial infarction segment is expected to contribute the highest share of the market, accounting for 37% in 2026. This is owing to its high prevalence and mortality rates globally.

The high incidence of myocardial infarction (MI) has boosted the demand for precise and early diagnosis of the condition. Since cardiac biomarkers play a crucial role in confirming suspected MIs by detecting heart muscle damage, their usage is concentrated majorly in MI diagnosis. Biomarkers like Troponins, CK-MB, and myoglobin allows clinicians to diagnose MI with higher accuracy than electrocardiograms or chest pain history alone. This supports clinicians in streamlining treatment decisions such as use of medications or angioplasty procedures.

Global Cardiac Biomarkers Market Insights, by Location of Testing

In terms of location of testing, laboratory testing is expected to contribute the highest share of the market, accounting for 71.6% of the market share in 2026 owing to its ability to offer higher sensitivity cardiac biomarker tests and a broader menu of tests compared to point-of-care formats.

Furthermore, clinical laboratories have the capability to run a wide spectrum of cardiac biomarker tests including those for myoglobin, CK-MB, and different Troponin isoforms. This expansive cardiac test menu supports laboratories in precisely characterizing widespread cardiac damage. Additionally, clinical laboratories have well-established processes, skilled personnel, and robust quality assurances in place to deliver reliable test results.

Regional Insights

North America Cardiac Biomarkers Market Trends

North America has dominated the global cardiac biomarkers market and is expected to continue its dominance over the forecast period. The region is expected to account for 40.7% of the market share in 2026. This can be attributed to the high prevalence of cardiovascular diseases in the U.S. and Canada coupled with growing elderly population.

In addition, well-established healthcare infrastructure and rising healthcare spending in the region are supporting the demand for advanced cardiac diagnostic tests. The presence of leading cardiac biomarkers manufacturers and availability of reimbursement are further propelling the market growth.

Asia Cardiac Biomarkers Market Trends and Growth Forecast

Asia Pacific has emerged as the fastest growing region in the global cardiac biomarkers industry. Rapid economic development, growing medical tourism industry, and rising chronic disease burden are the key factors fueling the market in Asia Pacific countries.

Additionally, increasing awareness about cardiac condition diagnosis and management is boosting the adoption of cardiac biomarkers. Leading global manufacturers are shifting their focus towards the Asia Pacific region in view of opportunities for business expansion. This has enhanced the accessibility to advanced testing technologies in the region.

 U.S. Cardiac Biomarkers Market Analysis

The U.S. cardiac biomarkers market is a rapidly growing sector, fueled by the rising burden of cardiovascular diseases and advancements in diagnostic technology. Troponin assays dominate, while point-of-care testing and AI integration are key trends driving market expansion, with major players actively innovating to meet growing demand for early and precise cardiac event detection.

India Cardiac Biomarkers Market Trends

India cardiac biomarkers market is seeing strong growth, driven by the increasing burden of heart diseases and a rising focus on early diagnosis. Troponin assays are particularly important due to their high accuracy. There's also a significant push towards point-of-care (POC) testing, which allows for quick results, critical for emergency care across diverse healthcare settings. 

Market Report Scope

Global Cardiac Biomarkers Industry News

• In May 2025, Cardiosense, a medical AI company, initiated the SEISMIC-HF II study to validate its machine learning algorithm for non-invasively assessing intracardiac filling pressure, an early indicator of acute heart failure.
• On May 27, 2025, Galmed Pharmaceuticals announced the discovery of a proprietary pharmacodynamic biomarker signature for Aramchol, revealing its potential beyond liver-focused applications into cardiometabolic and inflammatory conditions.
• An international research collaboration led by Johns Hopkins University, the Chinese University of Hong Kong, and Lund University identified 13 novel biomarkers that significantly improve the prediction of cardiovascular disease (CVD) risk in individuals with type 2 diabetes. The findings, published on January 25, 2024, address longstanding concerns about the limited effectiveness of traditional risk scores, particularly in diverse populations, despite type 2 diabetes being known to double the risk of CVD.
• On February 28, 2024, a study published in the Journal of the American Heart Association by researchers from Mass General Brigham identified six blood-based biomarkers that correlate with changes in arterial inflammation in individuals with rheumatoid arthritis (RA). The study, which analyzed 109 participants over a 24-week period, found that these biomarkers such as C-reactive protein, adiponectin, YKL-40, and others could significantly improve cardiovascular disease risk prediction in RA patients compared to conventional methods.
• In October 2023, Mindray, a global provider of medical devices and solutions, unveiled two new cardiac biomarkers, hs-cTnI and NT-proBNP, expanding its range of tools for diagnosing and treating cardiovascular diseases. The announcement was made through a recent statement, marking the global launch of these additions to Mindray's portfolio.

Analyst View

• The cardiac biomarkers market is swiftly moving beyond basic diagnosis toward prognostic and personalized medicine. This enables earlier risk stratification and customized treatment plans for individuals, shifting from a simple 'rule in/out' approach. It facilitates proactive and more tailored cardiac care.
• While foundational, troponin and BNP/NT-proBNP are increasingly joined by multiplex panels incorporating novel biomarkers like microRNAs. The growing integration of AI and machine learning is also key, enhancing data interpretation for more sophisticated predictive analytics and refined clinical decision-making.
• Overcoming regulatory complexities and biomarker variability is vital for broader adoption. Future success hinges on achieving greater assay standardization and establishing clear clinical guidelines, especially for emerging biomarkers and point-of-care technologies that promise to democratize cardiac care.

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2021 - 2033)
  • Myocardial Muscle Creatine Kinase (CK MB)
  • Myoglobin
  • Troponins (T and I)
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia-modified Albumin (IMA)
  • Others
• Application Insights (Revenue, USD Bn, 2021 - 2033)
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
•  Location of Testing Insights (Revenue, USD Bn, 2021 - 2033)
  • Laboratory Testing
  • Point of Care Testing
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Abbott Laboratories
  • Life Diagnostics
  • Roche Diagnostics
  • Siemens Healthineers
  • Danaher Corporation
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • PerkinElmer Inc.
  • bioMérieux SA
  • Randox Laboratories Ltd.
  • Ortho Clinical Diagnostics
  • Myriad RBM
  • DiaDexus Inc.
  • Response Biomedical Corp.
  • BG Medicine, Inc.
  • Boston Scientific Corporation
  • Cardiovascular Systems, Inc.
  • Quidel Corporation

Sources

Stakeholder:

• Senior Product Managers from Cardiac Biomarker Device Manufacturers
• Cardiac Biomarkers Industry Analysts
• Healthcare Professionals (Cardiologists and Laboratory Specialists)
• Key Decision Makers from Major Hospitals and Clinics
• Others

Databases:

• ScienceDirect
• ClinicalTrials.gov
• Others

Magazines:

• Diagnostic and Interventional Cardiology (DAIC)
• Clinical Lab Manager Magazine
• Medical Device and Diagnostic Industry (MD+DI)
• Others

Journals:

• Journal of the American College of Cardiology (JACC)
• Circulation (AHA Journals)
• Clinical Chemistry
• Others

Newspapers:

• The Guardian (Health Section)
• The New York Times (Medical and Healthcare – Cardiology)
• Healthcare Business Daily News
• Others

Associations:

• American Heart Association (AHA)
• American Association for Clinical Chemistry (AACC)
• European Society of Cardiology (ESC)
• American College of Cardiology (ACC)
• Others

Public Domain Sources:

• World Health Organization (WHO) Publications and Reports
• Centers for Disease Control and Prevention (CDC) Cardiac Data
• U.S. Food and Drug Administration (U.S. FDA) Medical Devices Portal
• European Medicines Agency (EMA) Cardiology Guidelines
• Others

Proprietary Elements:

• CMI Data Analytics Tool, Proprietary CMI Existing Repository of information for last 8 years.

*Definition: A cardiac biomarker refers to a protein-based substance that can be measured to analyze heart conditions for both prognostic and diagnostic purposes. These biomarkers are discharged into the bloodstream when the heart undergoes injury or stress, such as oxygen deprivation. Assessing cardiac biomarkers like cardiac troponin, creatinine kinase, and myoglobin, among others, aids in diagnosing various cardiovascular ailments like acute coronary syndrome (ACS) and cardiac ischemia.